Related Experiment Videos
Pharmacological modulation of cardiac fibroblast function
1Molecular Cardiology Lab, Philipps University of Marburg, Germany.
Herz
|April 1, 1995
Summary
Cardiac fibroblasts significantly impact heart structure and function. Targeting the renin-angiotensin-aldosterone system (RAAS) with agents like ACE inhibitors can prevent adverse cardiac remodeling and fibrosis.
Area of Science:
- Cardiovascular Biology
- Cardiac Fibrosis Research
- Myocardial Remodeling
Background:
- The cardiac interstitium, comprising nonmyocyte cells and structural proteins, dictates myocardial architecture and mechanical function.
- Cardiac fibroblasts are key regulators of collagen metabolism and fibrous tissue accumulation, influencing myocardial failure.
- Understanding fibroblast-mediated remodeling is crucial for treating cardiovascular diseases.
Purpose of the Study:
- To investigate the role of cardiac fibroblasts in myocardial structural remodeling.
- To explore the involvement of the renin-angiotensin-aldosterone system (RAAS) in fibroblast-mediated fibrosis.
- To identify potential pharmacologic targets for preventing adverse cardiac remodeling.
Main Methods:
- In vivo studies in rats with hypertension.
- In vitro studies using cultured adult cardiac fibroblasts.
- Analysis of collagen synthesis and matrix metalloproteinase activity.
Main Results:
- Renin-angiotensin-aldosterone system (RAAS) components are implicated in nonmyocyte structural remodeling.
- Angiotensin II (AngII) and aldosterone increase collagen synthesis in cardiac fibroblasts.
- AngII receptor blockade prevents the decrease in matrix metalloproteinase 1 activity.
Conclusions:
- Cardiac fibroblasts play a critical role in adverse myocardial structural remodeling.
- Pharmacologic inhibition of the RAAS (e.g., ACE inhibition, aldosterone receptor antagonism) prevents myocardial fibrosis.
- Targeting fibroblast-mediated fibrosis offers a promising therapeutic strategy for cardiovascular diseases.